bluebird bio sells itself to Carlyle, SK Capital
Carlyle and SK Capital to take gene therapy firm bluebird bio private
The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, bluebird stockholders will receive $3 per share in cash.
The Carlyle Group (NASDAQ:CG – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
(Reuters) - U.S.-based investment firm Carlyle Group has entered India's auto components market by buying a controlling stake ...
Carlyle Group Inc.’s stock fell 5% on Tuesday after the private-equity firm signaled a slowdown in its fee-related earnings ...
Bank of America Securities analyst Craig Siegenthaler maintained a Sell rating on Carlyle Group (CG – Research Report) yesterday and set a ...
AlpInvest Secondaries Fund VIII has raised nearly $9.4 billion as of 31 December 2024, according to materials prepared for ...
The Carlyle Group has announced the listing of its portfolio company Hexaware Technologies, a global IT services company, on the Bombay Stock Exchange and National Stock Exchange in India. The total ...
BofA analyst Craig Siegenthaler lowered the firm’s price target on Carlyle (CG) to $47 from $50 and keeps an Underperform rating on the shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback